Opinion|Videos|November 26, 2024
Utilizing Antibiotics in Treatment of C Difficile
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI).
- New therapies like fecal microbiota transplantation (FMT) and monoclonal antibodies aim to restore healthy gut flora and provide targeted immune support.
The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of antibiotics in the treatment of recurrent C difficile infections?
- Why was it necessary to develop new therapies beyond antibiotics?
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.
An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.
Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Risankizumab Outperforms Deucravacitinib in Moderate Plaque Psoriasis
5